TDP-43 vs Tau Pathology Determination in GRN vs MAPT Mutation Carriers
📖 Wiki Page
general808 wordssynced 2026-04-02
TDP-43 vs Tau Pathology Determination in GRN vs MAPT Mutation Carriers
Overview
Target Knowledge Gap: FTD Gap #1: "What determines whether TDP-43 vs tau pathology develops in GRN vs MAPT mutation carriers?" (Score: 33/40) — Both GRN and MAPT mutations cause FTD but produce different pathologies. Understanding the molecular switch could enable pathology-specific therapies.
Approximately 10-15% of FTD cases are caused by GRN (progranulin) or MAPT (tau) gene mutations. Despite both causing FTD:
GRN mutations → TDP-43 pathology (FTLD-TDP)
MAPT mutations → Tau pathology (FTLD-tau)
The fundamental question is: what molecular mechanisms determine which pathology develops? Understanding this "fate switch" could:
Enable targeted therapy development for each pathology type
Reveal whether pathology conversion is possible
Identify protective mechanisms applicable to both
Hypothesis
The pathology type is determined by a combination of:
Loss-of-function vs gain-of-function: GRN haploinsufficiency causes TDP-43 pathology through loss of nuclear TDP-43 function; MAPT mutations cause tau pathology through toxic gain-of-function
Cellular stress responses: Different cellular stress pathways trigger aggregation of either TDP-43 or tau
Post-translational modification patterns: PTM signatures that favor one aggregation pathway over another
Experimental Design
...
TDP-43 vs Tau Pathology Determination in GRN vs MAPT Mutation Carriers
Overview
Target Knowledge Gap: FTD Gap #1: "What determines whether TDP-43 vs tau pathology develops in GRN vs MAPT mutation carriers?" (Score: 33/40) — Both GRN and MAPT mutations cause FTD but produce different pathologies. Understanding the molecular switch could enable pathology-specific therapies.
Approximately 10-15% of FTD cases are caused by GRN (progranulin) or MAPT (tau) gene mutations. Despite both causing FTD:
GRN mutations → TDP-43 pathology (FTLD-TDP)
MAPT mutations → Tau pathology (FTLD-tau)
The fundamental question is: what molecular mechanisms determine which pathology develops? Understanding this "fate switch" could:
Enable targeted therapy development for each pathology type
Reveal whether pathology conversion is possible
Identify protective mechanisms applicable to both
Hypothesis
The pathology type is determined by a combination of:
Loss-of-function vs gain-of-function: GRN haploinsufficiency causes TDP-43 pathology through loss of nuclear TDP-43 function; MAPT mutations cause tau pathology through toxic gain-of-function
Cellular stress responses: Different cellular stress pathways trigger aggregation of either TDP-43 or tau
Post-translational modification patterns: PTM signatures that favor one aggregation pathway over another
Experimental Design
Study Design
Multi-center, multi-omics comparative study of GRN and MAPT mutation carriers
Model Systems
Primary: Induced pluripotent stem cells (iPSCs) from GRN and MAPT mutation carriers → differentiated cortical neurons
Secondary: Patient-derived brain tissue from FTD autopsy cases (GRN vs MAPT)
Validation: CRISPR-corrected iPSC lines to confirm mutation-specific effects
[Rascovsky K, et al, Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia (2011)](https://pubmed.ncbi.nlm.nih.gov/21810889/)
[Boxer AL, et al, Advancing research and treatment for frontotemporal lobar degeneration (ARTFL) (2019)](https://pubmed.ncbi.nlm.nih.gov/31683156/)
[Rohrer JD, et al, The heritability and genetics of frontotemporal lobar degeneration (2009)](https://pubmed.ncbi.nlm.nih.gov/1982288/)
Pathway Diagram
Mermaid diagram (expand to render)
Pathway Diagram
The following diagram shows the key molecular relationships involving TDP-43 vs Tau Pathology Determination in GRN vs MAPT Mutation Carriers discovered through SciDEX knowledge graph analysis: